Literature DB >> 25529856

Genetic variability testing of neurodevelopmental genes in schizophrenic patients.

Tea Terzić1, Matej Kastelic, Vita Dolžan, Blanka Kores Plesničar.   

Abstract

This study investigated the associations between single nucleotide polymorphisms in the neurodevelopmental Disrupted In Schizophrenia 1 (DISC1 ), neuregulin 1 (NRG1), brain-derived neurotrophic factor (BDNF) and NOTCH4 genes and the clinical symptoms and the occurrence of treatment-resistant schizophrenia in the Slovenian population. We included 138 schizophrenia patients, divided into treatment-responsive and treatment-resistant group and 94 healthy blood donors. All subjects were genotyped for eight polymorphisms (DISC1 rs6675281, DISC1 rs821616, NRG1 rs3735781, NRG1 rs3735782, NRG1 rs10503929, NRG1 rs3924999, BDNF rs6265, NOTCH rs367398) and investigated for associations with clinical variables. NOTCH4 rs367398 AA/AG was significantly associated with worse Positive and Negative Syndrome Scale (PANSS) and Clinical Global Impression (CGI) score. NOTCH4 rs367398 was not statistically significantly associated with the occurrence of treatment-resistant schizophrenia after the correction for multiple testing. Our data indicate that NOTCH4 polymorphism can influence clinical symptoms in Slovenian patients with schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25529856     DOI: 10.1007/s12031-014-0482-5

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  47 in total

Review 1.  Incidental neurodevelopmental episodes in the etiology of schizophrenia: an expanded model involving epigenetics and development.

Authors:  S M Singh; P McDonald; B Murphy; R O'Reilly
Journal:  Clin Genet       Date:  2004-06       Impact factor: 4.438

Review 2.  Brain Derived Neurotrophic Factor: a novel neurotrophin involved in psychiatric and neurological disorders.

Authors:  Sivasankaran Balaratnasingam; Aleksandar Janca
Journal:  Pharmacol Ther       Date:  2012-01-20       Impact factor: 12.310

3.  Association between BDNF Val66Met polymorphism and cognitive performance in antipsychotic-naïve patients with schizophrenia.

Authors:  Weihong Lu; Chen Zhang; Zhenghui Yi; Zezhi Li; Zhiguo Wu; Yiru Fang
Journal:  J Mol Neurosci       Date:  2012-04-03       Impact factor: 3.444

4.  Functional variants of the genes involved in neurodevelopment and susceptibility to schizophrenia in an Armenian population.

Authors:  Roksana Zakharyan; Anna Boyajyan; Arsen Arakelyan; Anaida Gevorgyan; Frantisek Mrazek; Martin Petrek
Journal:  Hum Immunol       Date:  2011-05-24       Impact factor: 2.850

5.  Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine.

Authors:  J Kane; G Honigfeld; J Singer; H Meltzer
Journal:  Arch Gen Psychiatry       Date:  1988-09

Review 6.  Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence.

Authors:  P J Harrison; D R Weinberger
Journal:  Mol Psychiatry       Date:  2005-01       Impact factor: 15.992

7.  NRG1 and BDNF genes in schizophrenia: an association study in an Italian case-control sample.

Authors:  Alessio Squassina; Paola Piccardi; Maria Del Zompo; Alessandro Rossi; Antonio Vita; Stefano Pini; Armida Mucci; Silvana Galderisi
Journal:  Psychiatry Res       Date:  2010-01-12       Impact factor: 3.222

8.  Age at onset and gender of schizophrenic patients in relation to neuroleptic resistance.

Authors:  H Y Meltzer; J Rabinowitz; M A Lee; P A Cola; R Ranjan; R L Findling; P A Thompson
Journal:  Am J Psychiatry       Date:  1997-04       Impact factor: 18.112

Review 9.  Chlorpromazine equivalent doses for the newer atypical antipsychotics.

Authors:  Scott W Woods
Journal:  J Clin Psychiatry       Date:  2003-06       Impact factor: 4.384

Review 10.  Heterogeneity of schizophrenia: Genetic and symptomatic factors.

Authors:  Sakae Takahashi
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2013-10       Impact factor: 3.568

View more
  4 in total

1.  A systematic meta-analysis of the association of Neuregulin 1 (NRG1), D-amino acid oxidase (DAO), and DAO activator (DAOA)/G72 polymorphisms with schizophrenia.

Authors:  Vinita Jagannath; Miriam Gerstenberg; Christoph U Correll; Susanne Walitza; Edna Grünblatt
Journal:  J Neural Transm (Vienna)       Date:  2017-09-01       Impact factor: 3.575

Review 2.  Theranostic Biomarkers for Schizophrenia.

Authors:  Matea Nikolac Perkovic; Gordana Nedic Erjavec; Dubravka Svob Strac; Suzana Uzun; Oliver Kozumplik; Nela Pivac
Journal:  Int J Mol Sci       Date:  2017-03-30       Impact factor: 5.923

3.  Clinical and Clinical-Pharmacogenetic Models for Prediction of the Most Common Psychiatric Complications Due to Dopaminergic Treatment in Parkinson's Disease.

Authors:  Sara Redenšek; Barbara Jenko Bizjan; Maja Trošt; Vita Dolžan
Journal:  Int J Neuropsychopharmacol       Date:  2020-11-26       Impact factor: 5.176

4.  Association of the NOTCH4 Gene Polymorphism rs204993 with Schizophrenia in the Chinese Han Population.

Authors:  Bao Zhang; Qian Rui Fan; Wen Hao Li; Ning Lu; Dong Ke Fu; Yan Jie Kang; Na Wang; Teng Li; Xiao Peng Wen; Da Xu Li
Journal:  Biomed Res Int       Date:  2015-10-28       Impact factor: 3.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.